Literature DB >> 18283297

Prostate cancer: genes, environment, immunity and the use of immunotherapy.

D Karan1, J B Thrasher, D Lubaroff.   

Abstract

Prostate cancer remains the most prevalent noncutaneous cancer, leading to almost 30,000 deaths every year in men in the United States. A large body of knowledge emphasizes a strong influence of epidemiological factors such as lifestyle, environment and diet, on the development of prostate cancer. Although risk reduction of prostate cancer has been somewhat successful, effective prevention is still lacking. Immunotherapeutic approaches, although moderately complicated, remain promising in an effort to control the progression and development of the disease. Taken together, the parameters of epidemiological studies and immunotherapeutic regimens might eventually be the most effective and preventive approach for prostate cancer. This review highlights some of the events associated with the development and prevention of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18283297     DOI: 10.1038/pcan.2008.3

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN: 1365-7852            Impact factor:   5.554


  11 in total

Review 1.  Cancer immunotherapy: a paradigm shift for prostate cancer treatment.

Authors:  Dev Karan; Jeffrey M Holzbeierlein; Peter Van Veldhuizen; J Brantley Thrasher
Journal:  Nat Rev Urol       Date:  2012-05-29       Impact factor: 14.432

Review 2.  The contrasting roles of inflammasomes in cancer.

Authors:  Qin He; Yu Fu; Dean Tian; Wei Yan
Journal:  Am J Cancer Res       Date:  2018-04-01       Impact factor: 6.166

Review 3.  Cyr61 is a potential prognostic marker for prostate cancer.

Authors:  Naoki Terada; Prakash Kulkarni; Robert H Getzenberg
Journal:  Asian J Androl       Date:  2012-02-20       Impact factor: 3.285

4.  Inflammation-associated regulation of the macrophage inhibitory cytokine (MIC-1) gene in prostate cancer.

Authors:  Seema Dubey; Peter Vanveldhuizen; Jeffrey Holzbeierlein; Ossama Tawfik; J Brantley Thrasher; Dev Karan
Journal:  Oncol Lett       Date:  2012-03-06       Impact factor: 2.967

5.  Cyr61 is regulated by cAMP-dependent protein kinase with serum levels correlating with prostate cancer aggressiveness.

Authors:  Naoki Terada; Takumi Shiraishi; Yu Zeng; Steven M Mooney; David B Yeater; Leslie A Mangold; Alan W Partin; Prakash Kulkarni; Robert H Getzenberg
Journal:  Prostate       Date:  2011-10-24       Impact factor: 4.104

Review 6.  Prostate Cancer: Epigenetic Alterations, Risk Factors, and Therapy.

Authors:  Mankgopo M Kgatle; Asgar A Kalla; Muhammed M Islam; Mike Sathekge; Razia Moorad
Journal:  Prostate Cancer       Date:  2016-11-06

7.  Polarization of M2 Macrophages by Interaction between Prostate Cancer Cells Treated with Trichomonas vaginalis and Adipocytes.

Authors:  Hyo-Yeoung Chung; Jung-Hyun Kim; Ik-Hwan Han; Jae-Sook Ryu
Journal:  Korean J Parasitol       Date:  2020-06-26       Impact factor: 1.341

8.  Caffeic Acid phenethyl ester as a potential treatment for advanced prostate cancer targeting akt signaling.

Authors:  Hui-Ping Lin; Ching-Yu Lin; Chun-Chieh Liu; Liang-Cheng Su; Chieh Huo; Ying-Yu Kuo; Jen-Chih Tseng; Jong-Ming Hsu; Chi-Kuan Chen; Chih-Pin Chuu
Journal:  Int J Mol Sci       Date:  2013-03-06       Impact factor: 5.923

Review 9.  From Inflammation to Prostate Cancer: The Role of Inflammasomes.

Authors:  Dev Karan; Seema Dubey
Journal:  Adv Urol       Date:  2016-06-27

10.  IL-6 produced by prostate epithelial cells stimulated with Trichomonas vaginalis promotes proliferation of prostate cancer cells by inducing M2 polarization of THP-1-derived macrophages.

Authors:  Ik-Hwan Han; Hyun-Ouk Song; Jae-Sook Ryu
Journal:  PLoS Negl Trop Dis       Date:  2020-03-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.